First, we used existing ChIP-seq data in the well-vetted high-grade serous ovarian cancer cell line OVCAR3 to identify active enhancers by searching for co-localization of the histone modification histone H3 lysine 27 acetylation (H3K27ac) and BRD4 (Fig. 1f)28–30. Here, BRD4 is linked to ovarian serous adenocarcinoma.